The worst luck in the world? The heart disease mutation carried by 60 million
MorphoSys AG and the University of Melbourne announced today that the U.S. Patent & Trademark Office (USPTO) has confirmed that it will issue U.S. Patent No. 7,455,836, covering key uses of antibodies against GM-CSF. The patent stems from a provisional patent application filed in the USPTO in 2000 by the University of Melbourne. In
Full Post: MorphoSys granted U.S. patent on antibodies against GM-CSF to treat inflammatory disorders
Heart disease is the number one killer in the world and India carries more than its share of this burden. Moreover, the problem is set to rise: it is predicted that by 2010 India’s population will suffer approximately 60% of the world’s heart disease.
Today, an international team of 25 scientists from four countries provides a clue to why this is so: 1% of the world’s population carries a mutation almost guaranteed to lead to heart problems and most of these come from the Indian subcontinent, where the mutation reaches a frequency of 4%.
Heart disease has many causes, some carried in our genes and others linked to our lifestyle, but all seemingly complex, hard to pin down and incompletely understood. So the new study published in Nature Genetics is striking for the size and simplicity of the effect it reports.
The mutation, a deletion of 25 letters of genetic code from the heart protein gene MYBPC3, is virtually restricted to people from the Indian subcontinent. But there, Caste and Tribe, Hindu, Muslim, Sikh, Christian and others are all united by this affliction.
The mutation was discovered five years ago in two Indian families with cardiomyopathy, but its significance only became apparent after almost 1500 people from many parts of India, some with heart disease and some without, were studied.
Scientists express this genetic risk as an odds ratio, where 1.2 would be a small effect and 2.0 a large one. For the MYBPC3 mutation, the odds ratio is almost off-scale, a staggering 7.0. Carriers usually show few symptoms until middle age, but after that age most are symptomatic and suffer from a range of effects, at worst sudden cardiac death.
“The mutation leads to the formation of an abnormal protein,” explained the study leader, Kumarasamy Thangaraj from the Centre for Cellular and Molecular Biology, Hyderabad, India. “Young people can degrade the abnormal protein and remain healthy, but as they get older it builds up and eventually results in the symptoms we see.”
The combination of such a large risk with such a high frequency is, fortunately, unique. “How can such a harmful mutation be so common?” asks Chris Tyler-Smith from The Wellcome Trust Sanger Institute, Hinxton, UK. “We might expect such a deleterious change to have ‘died out’.
“We think that the mutation arose around 30,000 years ago in India, and has been able to spread because its effects usually develop only after people have had their children. A case of chance genetic drift: simply terribly bad luck for the carriers.”
“The bad news is that many of these mutation carriers have no warning that they are in danger,” said Perundurai S. Dhandapany from Madurai Kamaraj University, Madurai, India, “but the good news is that we now know the impact of this mutation.”
The lifetime risk of developing heart failure is roughly one in five for a person aged 40 years. Now that this mutation has been identified, there is a new glimmer of hope for some of them. The mutation’s effects vary a lot from person to person. Carriers could be identified at a young age by genetic screening and adopt a healthier lifestyle.
“This is a genetic finding of great importance,” said Sir Mark Walport, Director of the Wellcome Trust. “Heart disease is one of the world’s leading killers, but now that researchers have identified this common mutation, carried by one in 25 people of Indian origin, we have hope of reducing the burden that the disease causes. This research should lead to better screening to identify those at risk and may ultimately allow the development of new treatments.”
And perhaps eventually new drugs could be developed to enhance the degradation of the abnormal protein and postpone the onset of symptoms. There is a market of 60 million people waiting.
A EU-India consortium led by Queen’s University Belfast has led to the development of technology which could provide safe drinking water for over 70 million people in South East Asia. The joint collaboration has resulted in the world’s first low-cost technology to provide arsenic-free water to people in India and surrounding countries. This week researchers
Full Post: Arsenic-free water provides hope to millions of people in South East Asia
Fatal Familiar Insomnia (FFI) is one of the diseases considered as rare - there are less than 100 cases described throughout the world. FFI prevents the patient getting to sleep to the point where she or he cannot ever sleep and which, after a number of months thus, causes death. ILF is a genetic illness
Full Post: Study looks at Fatal Familiar Insomnia
Identifying a single, common variation in a person’s genetic information improves prediction of his or her risk of a heart attack or other heart disease events and thus, choice of the best treatment accordingly, said researchers at Baylor College of Medicine in Houston. These findings are being presented at the American Heart Association’s Scientific Sessions in
Full Post: Genetics for personalized coronary heart disease treatment
Researchers at the University of Maryland School of Medicine in Baltimore have discovered a novel gene mutation among the Old Order Amish population that significantly reduces the level of triglycerides in the blood and appears to help prevent cardiovascular disease. The results of the study will be published in the Dec. 12, 2008, issue of
Full Post: Discovery of gene mutation that appears to help prevent heart disease
Severe combined immunodeficiency (SCID) is an inherited disease sometimes known as ‘Boy in the bubble syndrome’, because the patient lacks one or more type of immune cell, making them very susceptible to infections. Dik van Gent and colleagues, at Erasmus Medical Center, The Netherlands, have now identified a new genetic cause of SCID characterized by
Full Post: Discovery of new genetic cause severe combined immunodeficiency (SCID)